Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2026)

Monopar Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at -$3.4 million in Q4 2025.

• Quarterly Share-based Compensation fell 176.24% year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 72.93% YoY) and the FY2025 annual result came in at $16.4 million, up 260.26% from the prior year.
• Share-based Compensation retreated to -$3.4 million in Q4 2025 per MNPR's latest filing, from $8.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $9.8 million in Q1 2025 and troughed at -$3.4 million in Q4 2025.
• A 5-year average of $1.5 million and a median of $339412.5 in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 461.87% in 2023, then soared 5799.99% in 2025.
• Over 5 years, Share-based Compensation stood at $350164.0 in 2021, then advanced by 12.35% to $393417.0 in 2022, then tumbled by 461.87% to -$1.4 million in 2023, then surged by 417.14% to $4.5 million in 2024, then slumped by 176.24% to -$3.4 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered -$3.4 million, $8.6 million, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.